Extended-Release Tofacitinib Therapy for a MDA5 Antibody-Positive Amyopathic Dermatomyositis Patient with Early-Stage Interstitial Lung Disease.
Chrong-Reen WangWei-Chieh LinTak-Wah WongPublished in: ImmunoTargets and therapy (2023)
Owing to a rapid decline in higher mortality in anti-MDA5-positive ADM patients with ILD, early detection with prompt initiation of extended-release Tof induction therapy might achieve a beneficial outcome.
Keyphrases
- interstitial lung disease
- rheumatoid arthritis
- systemic sclerosis
- early stage
- breast cancer cells
- idiopathic pulmonary fibrosis
- mass spectrometry
- case report
- ms ms
- cardiovascular events
- disease activity
- cell cycle arrest
- risk factors
- squamous cell carcinoma
- type diabetes
- radiation therapy
- coronary artery disease
- signaling pathway
- cell death